Atezolizumab: a PD-L1 blocking antibody for bladder cancer

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

SPECIAL REPORT

Multiple Myeloma (MM)

Therapie des rezidivierten/refraktären Multiplen Myeloms

SPECIAL REPORT

Multiple Myeloma (MM)

Traitement du myélome multiple récidivant/réfractaire

SPECIAL REPORT

Breast Cancer

Du nouveau pour le cancer du sein triple négatif métastatique

Central Nervous System TumorsLung, Respiratory and Thoracic Cancer

Significant Survival Benefit of Atezolizumab in Second-Line NSCLC Regardless of PD-L1 Status (The OAK Study)

Lung, Respiratory and Thoracic Cancer

Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines

J Thorac Oncol.

Gagné A, Wang E, Bastien N, Orain M, Desmeules P, Pagé S, Trahan S, Couture C, Joubert D, Joubert P

doi: 10.1016/j.jtho.2019.08.2503.

Lung, Respiratory and Thoracic Cancer

Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer

J Thorac Oncol

Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC, Andric Z, Mocci S, Enquist I, Komatsubara K, McCleland M, Kuriki H, Villalobos M, Phan S, Spigel DR, Herbst RS

doi: 10.1016/j.jtho.2021.06.019

Breast Cancer

Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study

Eur J Cancer.

Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, Köhne CH, Solbach C, Ingold Heppner B, Steiger K, Müller V, Fasching P, Karn T, van Mackelenbergh M, Marmé F, Schmitt WD, Schem C, Stickeler E, Loibl S, Denkert C

doi: 10.1016/j.ejca.2019.04.010.

Genitourinary Cancer

Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing

Clin Cancer Res

Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, Farkas AM, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh WK, Szabo PM, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky MD

doi: 10.1158/1078-0432.CCR-20-4574

Related content

Recent Developments in Metastatic Breast Cancer

Therapie des rezidivierten/refraktären Multiplen Myeloms

Traitement du myélome multiple récidivant/réfractaire

Du nouveau pour le cancer du sein triple négatif métastatique

Significant Survival Benefit of Atezolizumab in Second-Line NSCLC Regardless of PD-L1 Status (The OAK Study)

Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines

Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer

Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study

Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing